GSKH - ETF AI Analysis
Top Page
GSK plc ADRhedged (GSKH)
Rating:74Outperform
Price Target:―
Positive Factors
Strong Main Holding
The ETF’s primary stock holding has shown strong year-to-date performance, helping support the fund’s overall returns.
Focused Health Care Exposure
Concentrating in the health care sector gives investors targeted exposure to a defensive industry that can be more resilient in economic slowdowns.
Low Expense Ratio
The fund’s relatively low ongoing fee means more of any gains can stay in investors’ pockets instead of going to costs.
Negative Factors
Extreme Single-Stock Concentration
With nearly the entire portfolio in one company, investors face high risk if that single stock runs into problems.
Recent Short-Term Weakness
The ETF has shown weak performance over the past one and three months, which may signal near-term volatility or pressure on returns.
Limited Geographic Diversification
Because the fund is almost entirely invested in U.S.-listed exposure, investors do not get much benefit from spreading risk across different regions.
GSKH vs. SPDR S&P 500 ETF (SPY)
AUM663.40K
RegionEurope
Expense Ratio0.19%
Beta0.19
IssuerADRhedged
Inception DateJan 07, 2025
Dividend Yield3.13%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume270
30 Day Avg. Volume343
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
90.53Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GSKH Summary
GSKH is an ETF that focuses on the pharmaceutical part of the healthcare sector and tracks the GSK plc – Benchmark Price Return index. It mainly holds shares of GlaxoSmithKline (GSK), a large global drug company known for vaccines and medicines. Investors might consider GSKH if they want simple, targeted exposure to a major pharmaceutical company, with some protection against foreign currency swings because it uses hedged ADRs. However, this ETF is highly concentrated in one company and industry, so its price can move sharply with news about GSK or changes in the healthcare sector.
How much will it cost me?The GSK plc ADRhedged ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it focuses on a specific niche in the pharmaceutical sector while offering currency hedging benefits.
What would affect this ETF?The GSKH ETF could benefit from positive trends in the pharmaceutical sector, such as advancements in drug development, regulatory approvals, and increased demand driven by aging populations and global health initiatives. However, it may face challenges from stricter regulations, patent expirations, or economic downturns that could impact healthcare spending. Additionally, its focus on the U.K. market and reliance on GlaxoSmithKline may expose it to risks tied to regional economic conditions or company-specific performance.
GSKH Top 10 Holdings
GSKH is essentially a one-stock story, with GlaxoSmithKline doing almost all the heavy lifting. The fund is tightly focused on the pharmaceutical corner of healthcare, and recent performance has been mixed: GSK has gained some ground year-to-date but has been lagging over the past few months, suggesting the rally is losing steam. Because the ETF is so heavily concentrated in this single U.K.-based pharma giant, investors are really betting on GSK’s pipeline, pricing power, and execution rather than a broad basket of healthcare names, with European exposure front and center.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| GlaxoSmithKline | 95.52% | $633.19K | $99.19B | 6.80% | 77 Outperform |
GSKH Technical Analysis
Negative
―
Price Trends
69.97
Negative
71.10
Negative
72.54
Negative
Market Momentum
-1.07
Positive
36.39
Neutral
16.64
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSKH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 69.15, equal to the 50-day MA of 69.97, and equal to the 200-day MA of 72.54, indicating a bearish trend. The MACD of -1.07 indicates Positive momentum. The RSI at 36.39 is Neutral, neither overbought nor oversold. The STOCH value of 16.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GSKH.
GSKH Peer Comparison
Comparison Results
Performance Comparison
GSKH
GSK plc ADRhedged
66.28
6.21
10.34%
ARMH
Arm Holdings PLC ADRhedged
―
―
―
HSBH
HSBC Holdings plc ADRhedged
―
―
―
SHEH
Shell plc ADRhedged
―
―
―
NVOH
Novo Nordisk A/S (B Shares) ADRhedged
―
―
―
BPH
BP p.l.c. ADRhedged
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents